Please login to the form below
moderate-to-severe atopic dermatitis
This page shows the latest moderate-to-severe atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.
Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
Sanofi and Regeneron’s Dupixent (dupilumab) was associated with significant improvements in moderate-to-severe atopic hand and foot dermatitis symptoms, according to phase 3 results presented at the American Academy ... The phase 3 trial evaluated
Latest news
-
Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
The medicine was approved by the US Food and Drug Administration in June 2022 for patients in this age group with moderate-to-severe atopic dermatitis. ... Young children with moderate-to-severe atopic dermatitis are a significantly underserved
-
MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis
patients, aged 12 years and older, with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. ... To date, tralokinumab is also approved for the treatment of adults with moderate-to-severe atopic dermatitis in Canada, the
-
Almirall granted EMA approval for lebrikizumab in atopic dermatitis
to-severe atopic dermatitis (AD). ... ADvocate 1 and ADvocate 2 assessed lebrikizumab as monotherapy in adult and adolescent patients with moderate-to-severe AD, while the ADhere trial assessed lebrikizumab as a combination treatment with topical
-
NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
LEO Pharma has announced that its biologic treatment for moderate-to-severe atopic dermatitis, Adtralza (tralokinumab), has been issued a final appraisal document for recommendation by the National Institute for Health ... In 2021, the European
-
Almirall shares positive topline results from atopic dermatitis trials
Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... atopic dermatitis.
More from news
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Meanwhile, phase 2b results for upadacitinib showed that the drug was able to improve skin lesions and itching in patients with moderate-to- severe atopic dermatitis (eczema) across all doses tested, ... Risankizumab is almost inevitably going to have a
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
